Huahua Zhong

12 Middle Wulumuqi Road
Shanghai, 200040, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications

Artificial Intelligence in Neuromuscular Diseases: Opportunities for a Data-Scarce Field.

Artificial Intelligence in Neuromuscular Diseases: Opportunities for a Data-Scarce Field.

Journal: Neurology and therapy
Published: March 31, 2026

Extended Preoperative Immunotherapy Duration Reduces the Risk of Myasthenia Gravis Exacerbation for Patients with Thymoma: A Multicenter Retrospective Cohort Study.

Extended Preoperative Immunotherapy Duration Reduces the Risk of Myasthenia Gravis Exacerbation for Patients with Thymoma: A Multicenter Retrospective Cohort Study.

Journal: Neurology and therapy
Published: March 13, 2026

Predictors of exacerbation in myasthenia gravis after minimal symptom expression: a bicenter cohort study.

Predictors of exacerbation in myasthenia gravis after minimal symptom expression: a bicenter cohort study.

Journal: Frontiers in immunology
Published: January 12, 2026

Application of Droplet Digital PCR in Sputum Samples in Myasthenia Gravis Patients with Pneumonia.

Application of Droplet Digital PCR in Sputum Samples in Myasthenia Gravis Patients with Pneumonia.

Journal: Infection and drug resistance
Published: December 15, 2025

PhenoRareAI: Phenotype-based intelligent diagnosis for rare neuromuscular disorders of glycogen storage disease and spinal muscular atrophy.

PhenoRareAI: Phenotype-based intelligent diagnosis for rare neuromuscular disorders of glycogen storage disease and spinal muscular atrophy.

Journal: Health information science and systems
Published: November 25, 2025

Eculizumab as a new option for perioperative treatment in thymoma-associated myasthenia gravis.

Eculizumab as a new option for perioperative treatment in thymoma-associated myasthenia gravis.

Journal: Clinical immunology (Orlando, Fla.)
Published: October 13, 2025

Targeting pathogenic Th17.1 cells via JAK-STAT3 pathway: A novel approach with tofacitinib for refractory myasthenia gravis.

Targeting pathogenic Th17.1 cells via JAK-STAT3 pathway: A novel approach with tofacitinib for refractory myasthenia gravis.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: October 11, 2025

1-Year Clinical Outcome Post-Myasthenic Crisis: A Multicenter Prospective Study in China.

1-Year Clinical Outcome Post-Myasthenic Crisis: A Multicenter Prospective Study in China.

Journal: European journal of neurology
Published: October 06, 2025

A comprehensive framework for the interpretation of TTN missense variants.

A comprehensive framework for the interpretation of TTN missense variants.

Journal: Genome medicine
Published: July 17, 2025

Efgartigimod versus standard of care in new-Onset AChR subtype generalized myasthenia gravis: A prospective cohort study.

Efgartigimod versus standard of care in new-Onset AChR subtype generalized myasthenia gravis: A prospective cohort study.

Journal: Clinical immunology (Orlando, Fla.)
Published: July 05, 2025

Translation of GGC repeats into a toxic polyglycine protein in oculopharyngodistal myopathy type 2.

Translation of GGC repeats into a toxic polyglycine protein in oculopharyngodistal myopathy type 2.

Journal: Brain : a journal of neurology
Published: February 20, 2025

Serum cystatin C as a potential biomarker for generalized acetylcholine receptor antibody-positive myasthenia gravis.

Serum cystatin C as a potential biomarker for generalized acetylcholine receptor antibody-positive myasthenia gravis.

Journal: Frontiers in immunology
Published: February 17, 2025
Showing 1-12 of 39

Last Updated: 09/26/2026